Prof Frédérique Penault-Llorca, MD
Chief Executive Officer
Jean Perrin Comprehensive Cancer Center
Professor of Pathology
Head of the Department of Pathology and Tumor Biology
Clermont-Ferrand, France
Chief Executive Officer
Jean Perrin Comprehensive Cancer Center
Professor of Pathology
Head of the Department of Pathology and Tumor Biology
Clermont-Ferrand, France
Related Videos
Using the FoundationOne Report as an example, can you explain what information should ideally appear on an NGS report and what interpretative dimensions of the report are necessary to optimize its clinical value as treatment roadmap?
Can you provide specific patient examples where longitudinal assessment with a combination of tissue-based NGS and ctDNA can provide a more detailed roadmap of targeted therapy?
There is a lot of uncertainty about the use of liquid biopsies (ctDNA). Can you identify situations where analysis of ctDNA may be complementary to NGS-based assessment of tissue samples?
What kind of specific, actionable information is contained on an NGS CGP report? In what context is hybrid capture-based NGS especially valuable at the front lines of precision cancer care?
Among such solid tumors as NSLC, melanoma, colorectal, and breast cancers, approximately what percentage of patients will have actionable genomic alterations—EGFR, ALK, HER-2, RAS, and others—that are detected by FoundationOne or other ...